Clinical Trial: Bevacizumab for Primary Pterygium Treatment

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Conjunctival Autografting Alone or Combined With Subconjunctival Bevacizumab for Primary Pterygium Treatment.

Brief Summary: The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.

Detailed Summary:
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana

Current Primary Outcome: Pterygium recurrence [ Time Frame: One point. ]

The pterygium recurrence is evaluated at one year postoperative


Original Primary Outcome: Same as current

Current Secondary Outcome: Conjunctival ischemia [ Time Frame: Ischemia is measured at 24 h, 1 week, 15 days, six months and one year postoperative ]

Whiteness of conjunctival bed, that means absence of blood vessels


Original Secondary Outcome: Same as current

Information By: Instituto de Oftalmología Fundación Conde de Valenciana

Dates:
Date Received: September 11, 2012
Date Started: March 2010
Date Completion:
Last Updated: December 5, 2013
Last Verified: December 2013